ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

Browse : By Sponsor : National Institutes of Health : National Cancer Institute (NCI)


Include trials that are no longer recruiting patients.

3563 studies were found. Here are studies 1 to 50.
1.No longer recruiting(1)H-Nuclear Magnetic Resonance Spectroscopic Imaging of the Brain in Patients who Receive Neurotoxic Therapy
Conditions: Cancer; Central Nervous System Disease; Nervous System Disease; Peripheral Nervous System Disease; Progressive Multifocal Leukoencephalopathy
2.Suspended10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Conditions: adult Hodgkin's lymphoma; adult non-Hodgkin's lymphoma
3.No longer recruiting10-Propargyl-10-Deazaaminopterin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer; Quality of Life
4.Completed10-Propargyl-10-Deazaaminopterin Plus Probenecid in Treating Patients With Advanced Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
5.Recruiting12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Conditions: chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
6.Recruiting17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Conditions: adult solid tumor; Leukemia; Lymphoma; small intestine cancer
7.Recruiting17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
Condition: Cancer
8.Recruiting17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
Conditions: adult solid tumor; Leukemia; Lymphoma
9.Recruiting17-DMAG to Treat Patients with Solid Tumors or Lymphomas
Conditions: Neoplasms; Lymphoma
10.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
Condition: unspecified adult solid tumor, protocol specific
11.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Condition: Cancer
12.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Kidney Cancer
Conditions: recurrent renal cell cancer; Stage IV Renal Cell Cancer; renal clear cell carcinoma
13.Suspended17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer
Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
14.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
Conditions: adult Hodgkin's lymphoma; adult T-cell leukemia and lymphoma; adult non-Hodgkin's lymphoma; adult solid tumor; Cutaneous T-Cell Lymphoma; ...
15.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma
Conditions: stage III melanoma; Stage IV Melanoma; Recurrent Melanoma
16.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
Conditions: stage I renal cell cancer; von Hippel-Lindau Syndrome
17.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
Conditions: Ewing's family of tumors; childhood rhabdomyosarcoma; childhood soft tissue sarcoma; hematopoietic and lymphoid cancer; Neuroblastoma; Osteosarcoma
18.Recruiting17-N-Allylamino-17-Demethoxygeldanamycin in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Conditions: unspecified childhood solid tumor, protocol specific; recurrent childhood acute lymphoblastic leukemia; recurrent childhood acute myeloid leukemia; ...
19.Recruiting17AAG to Treat Kidney Tumors in von Hippel-Lindau Disease
Conditions: Hippel-Lindau Disease; Kidney Cancer
20.No longer recruiting2-Methoxyestradiol (2-ME2) to Treat Solid Tumor Cancers
Conditions: Pathologic Angiogenesis; Neoplasm
21.Recruiting2-Methoxyestradiol in Treating Patients With Advanced Solid Tumors
Conditions: refractory plasma cell neoplasm; stage III multiple myeloma; unspecified adult solid tumor, protocol specific
22.Not yet recruiting3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer; peritoneal cavity cancer
23.Recruiting3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
Condition: unspecified adult solid tumor, protocol specific
24.Recruiting3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer
Conditions: recurrent non-small cell lung cancer; stage IV non-small cell lung cancer
25.Recruiting3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
Condition: Non-small cell lung cancer
26.Recruiting3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
27.Recruiting3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
Conditions: unresectable extrahepatic bile duct cancer; recurrent gallbladder cancer; unresectable gallbladder cancer; recurrent extrahepatic bile duct cancer; ...
28.Recruiting3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
Conditions: adult acute lymphoblastic leukemia; adult acute myeloid leukemia; Chronic Myelogenous Leukemia; secondary acute myeloid leukemia
29.Recruiting3-AP as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Adenocarcinoma (Cancer) of the Pancreas
Conditions: adenocarcinoma of the pancreas; recurrent pancreatic cancer; stage II pancreatic cancer; stage III pancreatic cancer; stage IVA pancreatic cancer; ...
30.Recruiting3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Conditions: acute leukemia; adult acute monoblastic and acute monocytic leukemia; atypical chronic myeloid leukemia; chronic leukemia; ...
31.Suspended3-AP in Treating Patients With Previously Untreated Locally Recurrent or Metastatic Renal Cell Carcinoma
Conditions: recurrent renal cell cancer; stage III renal cell cancer; Stage IV Renal Cell Cancer
32.Recruiting3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Conditions: recurrent esophageal cancer; stage IV esophageal cancer; Adenocarcinoma of the Esophagus
33.Recruiting3-Dimensional Conformal Radiation Therapy In Treating Women With Stage I or Stage II Breast Cancer Previously Treated With Lumpectomy and Axillary Node Dissection
Conditions: stage I breast cancer; stage II breast cancer
34.No longer recruiting4'-Iodo-4'-deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
Condition: primary systemic amyloidosis
35.Completed506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
Conditions: refractory chronic lymphocytic leukemia; T-cell chronic lymphocytic leukemia; B-cell Chronic Lymphocytic Leukemia
36.No longer recruiting506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Conditions: Leukemia; Lymphoma; Multiple Myeloma
37.No longer recruiting506U78 in Treating Patients With Lymphoma
Conditions: Leukemia; Lymphoma
38.Suspended506U78 in Treating Patients With Recurrent or Refractory Acute Lymphocytic Leukemia
Conditions: recurrent adult acute lymphoblastic leukemia; L1 adult acute lymphoblastic leukemia; L2 adult acute lymphoblastic leukemia; ...
39.No longer recruiting506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
Conditions: recurrent cutaneous T-cell lymphoma; recurrent mycosis fungoides/Sezary syndrome
40.No longer recruiting506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
Conditions: recurrent diffuse small lymphocytic/marginal zone lymphoma; recurrent adult T-cell leukemia/lymphoma; angioimmunoblastic T-cell lymphoma; ...
41.No longer recruiting506U78 in Treating Patients With Refractory Hematologic Cancer
Conditions: recurrent childhood lymphoblastic lymphoma; T-cell childhood acute lymphoblastic leukemia; recurrent childhood acute lymphoblastic leukemia
42.No longer recruiting506U78 in Treating Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Conditions: recurrent adult lymphoblastic lymphoma; recurrent adult T-cell leukemia/lymphoma; recurrent childhood lymphoblastic lymphoma; ...
43.Recruiting506U78 in Treating Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
Conditions: recurrent adult acute lymphoblastic leukemia; T-cell adult acute lymphoblastic leukemia; recurrent adult lymphoblastic lymphoma
44.No longer recruiting6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Colorectal Cancer
Conditions: recurrent colon cancer; Stage IV rectal cancer; adenocarcinoma of the colon; adenocarcinoma of the rectum; recurrent rectal cancer; ...
45.Completed6-Hydroxymethylacylfulvene in Treating Patients With Metastatic Kidney Cancer
Conditions: Stage IV Renal Cell Cancer; recurrent renal cell cancer
46.No longer recruiting6-Hydroxymethylacylfulvene in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Conditions: recurrent colon cancer; adenocarcinoma of the rectum; Stage IV rectal cancer; recurrent rectal cancer; stage IV colon cancer; ...
47.Completed6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
Conditions: Previously Treated Myelodysplastic Syndrome; secondary myelodysplastic syndrome; recurrent adult acute myeloid leukemia; ...
48.No longer recruiting6-Hydroxymethylacylfulvene in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Conditions: Adenocarcinoma of the Lung; large cell lung cancer; Squamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; recurrent non-small cell lung cancer
49.Completed6-Hydroxymethylacylfulvene in Treating Patients With Stage IV Melanoma
Condition: Stage IV Melanoma
50.Completed6-Hydroxymethylacylfulvene in Treating Patients With Stage IVB or Recurrent Cervical Cancer
Conditions: recurrent cervical cancer; cervical adenocarcinoma; cervical squamous cell carcinoma; cervical adenosquamous cell carcinoma; ...

line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act